C-Rad 미래 성장

Future 기준 확인 5/6

C-Rad (는) 각각 연간 34.7% 및 14.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 34.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 24.5% 로 예상됩니다.

주요 정보

34.7%

수익 성장률

34.8%

EPS 성장률

Medical Equipment 수익 성장	22.5%
매출 성장률	14.8%
향후 자기자본 수익률	24.5%
애널리스트 커버리지	Low
마지막 업데이트	25 Oct 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

LSE:0R44 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (SEK Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	679	121	87	N/A	1
12/31/2025	598	89	60	N/A	1
12/31/2024	517	61	46	N/A	1
9/30/2024	486	58	38	48	N/A
6/30/2024	497	54	68	81	N/A
3/31/2024	458	48	47	62	N/A
12/31/2023	425	36	16	33	N/A
9/30/2023	385	24	-3	14	N/A
6/30/2023	357	20	-27	-13	N/A
3/31/2023	329	12	-11	3	N/A
12/31/2022	301	7	-2	10	N/A
9/30/2022	280	14	-16	-9	N/A
6/30/2022	260	12	-6	1	N/A
3/31/2022	257	21	6	12	N/A
12/31/2021	261	25	12	18	N/A
9/30/2021	258	26	16	23	N/A
6/30/2021	247	25	30	36	N/A
3/31/2021	230	17	26	32	N/A
12/31/2020	222	14	12	18	N/A
9/30/2020	198	-11	2	9	N/A
6/30/2020	201	-16	-13	-4	N/A
3/31/2020	210	-14	-19	-7	N/A
12/31/2019	205	-14	5	16	N/A
9/30/2019	212	23	-4	5	N/A
6/30/2019	203	24	7	14	N/A
3/31/2019	204	27	9	13	N/A
12/31/2018	190	21	-14	-10	N/A
9/30/2018	174	-2	-11	-8	N/A
6/30/2018	161	-4	N/A	-6	N/A
3/31/2018	141	-10	N/A	-13	N/A
12/31/2017	133	-11	N/A	-4	N/A
9/30/2017	118	-16	N/A	-12	N/A
6/30/2017	108	-23	N/A	-36	N/A
3/31/2017	90	-28	N/A	-37	N/A
12/31/2016	83	-31	N/A	-45	N/A
9/30/2016	74	-33	N/A	-40	N/A
6/30/2016	70	-32	N/A	-31	N/A
3/31/2016	73	-27	N/A	-27	N/A
12/31/2015	73	-21	N/A	-23	N/A
9/30/2015	73	-20	N/A	-19	N/A
6/30/2015	66	-16	N/A	-19	N/A
3/31/2015	62	-8	N/A	-14	N/A
12/31/2014	57	-7	N/A	-13	N/A
9/30/2014	56	-5	N/A	-8	N/A
6/30/2014	59	-4	N/A	-12	N/A
3/31/2014	52	-17	N/A	-29	N/A
12/31/2013	49	-21	N/A	-23	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 0R44 의 연간 예상 수익 증가율( 34.7% )이 saving rate( 1.9% 보다 높습니다. ).

수익 vs 시장: 0R44 의 연간 수익( 34.7% ) UK 시장( 14.6% 보다 빠르게 성장할 것으로 예상됩니다. 14.6% 연간).

고성장 수익: 0R44 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: 0R44 의 수익(연간 14.8% ) UK 시장( 3.6% 보다 빠르게 성장할 것으로 예상됩니다. 3.6% 연간).

고성장 수익: 0R44 의 수익(연간 14.8% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 0R44 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 24.5 %)

C-Rad 미래 성장

Future 기준 확인 5/6

주요 정보

최근 미래 성장 업데이트

Recent updates

C-Rad AB (publ) to Report Q3, 2025 Results on Oct 23, 2025

Independent Director recently bought kr190k worth of stock

New minor risk - Market cap size

Third quarter 2024 earnings released: EPS: kr0.45 (vs kr0.32 in 3Q 2023)

CEO & President recently bought kr85k worth of stock

Second quarter 2024 earnings released: EPS: kr0.31 (vs kr0.16 in 2Q 2023)

Full year 2023 earnings released: EPS: kr1.05 (vs kr0.22 in FY 2022)

C-Rad AB (publ) Appoints Mats Thorén as Board Member

C-Rad AB (publ) to Report Fiscal Year 2023 Results on Apr 23, 2024

Full year 2023 earnings released: EPS: kr1.36 (vs kr0.22 in FY 2022)

C-Rad AB (publ) to Report Q3, 2024 Results on Oct 23, 2024

Third quarter 2023 earnings released

Investor sentiment improves as stock rises 17%

Less than half of directors are independent

C-Rad AB (Publ) Announces Former Employee Appeals Verdict from the Patent and Market Court of Appeal

New major risk - Earnings quality

C-Rad AB (publ) to Demonstrate Enhancements in Surface Guided Solutions for Advanced Radiotherapy Treatments at AAPM

Second quarter 2023 earnings released

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

C-Rad AB (publ) to Report Fiscal Year 2022 Final Results on Apr 06, 2023

C-Rad AB (Publ) Appoints Christoffer Herou as CFO

C-Rad AB (Publ) Announces CEO Changes

C-Rad AB (publ) Announces CFO Changes

C-Rad AB (publ) to Report Q3, 2023 Results on Oct 27, 2023

C-RAD Launches New Updated eDucation Portal as an Online Platform

Second quarter 2022 earnings released

Henrik Bergentoft Resigns as CFO of C-RAD

C-Rad Announces CEO Changes

Insufficient new directors

Insufficient new directors

C-Rad AB (publ) to Report Q3, 2022 Results on Oct 28, 2022

C-Rad Achieves Another Milestone Ensuring the Availability of SGRT, the Standard of Care for Radiotherapy

Third quarter 2021 earnings released

Chief Operating Officer recently sold kr625k worth of stock

Second quarter 2021 earnings released

C-Rad AB (publ) Announces The Patent and Market Court Rejected Former Employee Claim for Compensation

The Patent and Market Court of Appeal Issues Judgement Confirming C-Rad's Entitlement to Beamocular's Invention

Full year 2020 earnings released: EPS kr0.43 (vs kr0.45 loss in FY 2019)

C-RAD and Alliance Radiation Oncology Announce That Alliance Has Become the First Center in the Greater Northshore Area to Integrate C-Rad

C-Rad and With-Global Engages in a Partnership for the South Korean Market

C-RAD Receives Order for Proton Cancer Treatment Centers in the US

Shenzhen Proton Therapy Treatment Center Selects C-Rad Catalyst™ System

C-Rad AB (publ) to Report Q2, 2021 Results on Jul 29, 2021

Shanghai Proton and Heavy Ion Hospital Decides for C-Rad Sigrt Solution

Australian Customers Select C-RAD’s Cutting Edge SIGRT Solution

C-Rad AB Receives SEK 11 Million Order for Cutting Edge SIGRT Solution by DTZ in Berlin

Independent Director recently sold kr672.4k worth of stock

Independent Director recently bought kr1.7m worth of stock

Independent Director recently sold kr3.4m worth of stock

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견